J. Pers. Med., 2022 · DOI: 10.3390/jpm12091485 · Published: September 10, 2022
This article discusses the potential role of patient-derived iPSCs in neurological diseases and their contribution to scientific and clinical research for developing disease models and for developing a roadmap for future medicine. The contribution of humaniPSCs in the most common neurodegenerative diseases (e.g., Parkinson’s disease and Alzheimer’s disease, diabetic neuropathy, stroke, and spinal cord injury) were examined and ranked as per their published literature on PUBMED. Recent advancements in the field of personalized medicine, such as the patient-on-a-chip concept, where iPSCs can be grown on 3D matrices inside microfluidic devices to create an in vitro disease model for personalized medicine, are explored.
iPSCs provide a platform for large-scale in vitro drug screening of chemical libraries, facilitating the identification of potential molecules for drug development and cytotoxicity studies.
Patient-specific iPSCs allow for researching a wide range of incurable disorders, such as neurodegenerative diseases of the CNS, heart infarction, diabetes mellitus, and liver, lung, and kidney disease.
iPSCs can be used in regenerative medicine to repair cells or tissues damaged due to aging, chronic diseases, neurological diseases, congenital abnormalities, etc.